Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Effective ways to prevent arthropathy in severe hemophilia are unknown. METHODS: We randomly assigned young boys with severe hemophilia A to regular infusions of recombinant factor VIII (prophylaxis) or to an enhanced episodic infusion schedule of at least three doses totaling a minimum of 80 IU of factor VIII per kilogram of body weight at the time of a joint hemorrhage. The primary outcome was the incidence of bone or cartilage damage as detected in index joints (ankles, knees, and elbows) by radiography or magnetic resonance imaging (MRI). RESULTS: Sixty-five boys younger than 30 months of age were randomly assigned to prophylaxis (32 boys) or enhanced episodic therapy (33 boys). When the boys reached 6 years of age, 93% of those in the prophylaxis group and 55% of those in the episodic-therapy group were considered to have normal index-joint structure on MRI (P=0.006). The relative risk of MRI-detected joint damage with episodic therapy as compared with prophylaxis was 6.1 (95% confidence interval, 1.5 to 24.4). The mean annual numbers of joint and total hemorrhages were higher at study exit in the episodic-therapy group than in the prophylaxis group (P<0.001 for both comparisons). High titers of inhibitors of factor VIII developed in two boys who received prophylaxis; three boys in the episodic-therapy group had a life-threatening hemorrhage. Hospitalizations and infections associated with central-catheter placement did not differ significantly between the two groups. CONCLUSIONS: Prophylaxis with recombinant factor VIII can prevent joint damage and decrease the frequency of joint and other hemorrhages in young boys with severe hemophilia A. (ClinicalTrials.gov number, NCT00207597 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although effective, ERT is limited by an approximately 40% noncompliance rate, costs ≥$200,000 annually, and advances arthropathy.172, 173, 174, 175”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [172]
Citations
Cites
Twenty‐five years' experience of prophylactic treatment in severe haemophilia A and B
NILSSON, I. M., BERNTORP, E., LÖFQVIST, T., & PETTERSSON, H. (1992) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1992.tb00546.x · Cited by 961
A longitudinal study of orthopaedic outcomes for severe factor‐VIII‐deficient haemophiliacs
ALEDORT, L. M., HASCHMEYER, R. H., PETTERSSON, H., & THE ORTHOPAEDIC OUTCOME STUDY GROUP (1994) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1994.tb00815.x · Cited by 611
A Radiologic Classification of Hemophilic Arthropathy
PETTERSSON, H., AHLBERG, Å., & NILSSON, I. M. (1980) · Clinical Orthopaedics and Related Research · doi:10.1097/00003086-198006000-00018 · Cited by 549
Proceedings: A more uniform measurement of factor VIII inhibitors.
Ck, K., Aledort, L. M., Aronson, D. D., Counts, R., Edson, van Eys, J., Fratantoni, J. C., Green, D., Hampton, J., Hilgartner, M. W., et al. (1975) · PubMed · Cited by 346
Barriers to compliance with prophylaxis therapy in haemophilia
Hacker, M. R., Geraghty, S., & Manco-Johnson, M. (2001) · Haemophilia · doi:10.1046/j.1365-2516.2001.00534.x · Cited by 261
Self-citationAhlberg, Å. (1965) · Acta Orthopaedica Scandinavica · doi:10.3109/ort.1965.36.suppl-77.01 · Cited by 252
Joint range-of-motion limitations among young males with hemophilia: prevalence and risk factors
Soucie, J. M. (2004) · Blood · doi:10.1182/blood-2003-05-1457 · Cited by 244
Self-citationIorio, A., Marchesini, E., Marcucci, M., Stobart, K., & Chan, A. K. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003429.pub4 · Cited by 192
Nuss, R., Kilcoyne, R. F., Geraghty, S., Shroyer, A. L. W., Rosky, J. W., Mawhinney, S., Wiedel, J., & Manco‐Johnson, M. (2000) · Haemophilia · doi:10.1046/j.1365-2516.2000.00383.x · Cited by 159
Self-citationLee, C. A., Kessler, C. M., Varon, D., Martinowitz, U. P., Heim, M., Kreuz, W., Escuriola‐Ettingshausen, C., Funk, M. J., SCHMIDT, H., & Kornhuber, B. (1998) · Haemophilia · doi:10.1046/j.1365-2516.1998.440413.x · Cited by 154
Research works printed but not linked: 5
- Robinson PM, 1967, Can Med Assoc J, 97, 559
- Medical and Scientific Advisory Council (MASAC) recommendations concerning prophylaxis. Medical bulletin #193. New York: National Hemophilia Foundation, March 11, 1994.
- Stobart K, 2006, Cochrane Database Syst Rev, 2, CD003429
- Kasper CK, 1975, Thromb Diath Haemorr, 34, 612
- Report on the Universal Data Collection Program. Atlanta: Centers for Disease Control and Prevention, 2005;7(1):28. (Accessed July 18, 2007, athttp://www.cdc.gov/ncbddd/hbd/documents/UDC7%281%29.pdf.)
Cited by
Items 801–900 of 1,000
Bhatt, N., Boggio, L. N., & Simpson, M. L. (2021) · Haemophilia · doi:10.1111/hae.14228 · Cited by 17
Swan, D., Paran, S., & Nolan, B. (2021) · Haemophilia · doi:10.1111/hae.14459 · Cited by 15
Wada, H., Shiraki, K., Matsumoto, T., Suzuki, K., Yamashita, Y., Tawara, I., Shimpo, H., & Shimaoka, M. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11206142 · Cited by 15
“Although prophylactic treatment with coagulation factor VIII (FVIII) concentrate is preferred to prevent bleeding and joint damage in children with severe hemophilia [2,3], there are still several risk factors for the treatment of hemophilia A [4].”
BackgroundNagao, A., Inagaki, Y., Nogami, K., Yamasaki, N., Iwasaki, F., Liu, Y., Murakami, Y., Ito, T., & Takedani, H. (2024) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2024.102439 · Cited by 19
“Magnetic resonance imaging (MRI) data have shown joint damage in a proportion of people with hemophilia who had no evidence of joint bleeds, with the damage speculated to be related to chronic subclinical bleeding [4].”
Backgroundfor the Canadian Hemophilia Primary Prophylaxis (CHPS) Study Group, Abrahamyan, L., Willan, A. R., Beyene, J., McLimont, M., Blanchette, V. S., & Feldman, B. M. (2014) · Journal of General Internal Medicine · doi:10.1007/s11606-014-2880-3 · Cited by 17
Prevention of haemarthrosis in a murine model of acute joint bleeding
Valentino, L. A., HAKOBYAN, N., Kazarian, T., Sørensen, B. B., & Tranholm, M. (2008) · Haemophilia · doi:10.1111/j.1365-2516.2008.01870.x · Cited by 15
Self-citationFranchini, M., Coppola, A., Rocino, A., Zanon, E., Morfini, M., Accorsi, A., Aru, A. B., Biasoli, C., Cantori, I., Castaman, G., et al. (2014) · Haemophilia · doi:10.1111/hae.12334 · Cited by 15
Janbain, M., Enjolras, N., Bordet, J., Bolbos, R. I., Brevet, M., Leissinger, C., & Dargaud, Y. G. (2019) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14694 · Cited by 15
Self-citationCuesta‐Barriuso, R., Donoso‐Úbeda, E., Meroño‐Gallut, J., Pérez‐Llanes, R., & Pina, J. A. L. (2020) · Musculoskeletal Science and Practice · doi:10.1016/j.msksp.2020.102194 · Cited by 15
Lambert, C., Meité, N., Sanogo, I., Lobet, S., & Hermans, C. R. J. R. (2020) · Haemophilia · doi:10.1111/hae.14216 · Cited by 15
Coppola, A., Franchini, M., Pappagallo, G. L., Borchiellini, A., CRISTOFARO, R. D., Molinari, A. C., Santoro, R., Santoro, C., & Tagliaferri, A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11030801 · Cited by 20
Long‐term joint outcomes in adolescents with moderate or severe haemophilia A
Schmidt, D. E., Michalopoulou, A., Fischer, K., Motwani, J., Andersson, N. G., Pergantou, H., Ranta, S., & the PedNet Study Group (2022) · Haemophilia · doi:10.1111/hae.14636 · Cited by 15
Minno, M. N. D. D., Martinoli, C., Pasta, G., la Corte‐Rodríguez, H. D., Samy, I., Stephensen, D., Timmer, M. A., & Winburn, I. C. (2022) · Haemophilia · doi:10.1111/hae.14657 · Cited by 15
Autoimmunity: Are we asking the right question?
Matzinger, P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.864633 · Cited by 19
Lane, H. D., Siddiqi, A., Ingram‐Rich, R., Tobase, P., Ward, R. S., & Universal Data Collection Joint Outcome Working Group (2014) · Haemophilia · doi:10.1111/hae.12398 · Cited by 15
“In a randomized controlled trial of prophylaxis vs. enhanced episodic factor replacement therapy, Manco-Johnson et al. [4] found 18 abnormal joints in 15 of 65 children enrolled, all under the age of 6 years.”
Salinas, V., Carmona, R., Mohammed, B. M., Martin, E. J., Brophy, D. F., & Young, G. A. (2014) · Haemophilia · doi:10.1111/hae.12578 · Cited by 15
Advances in the Care and Treatment of Children with Hemophilia
Manco‐Johnson, M. J. (2010) · Advances in Pediatrics · doi:10.1016/j.yapd.2010.08.007 · Cited by 15
Self-citationManagement of bleeding disorders in children
Berntorp, E. E., Halimeh, S., Gringeri, A., Mathias, M., Escuriola, C., & Pérez, R. M. Á. (2012) · Haemophilia · doi:10.1111/j.1365-2516.2012.02796.x · Cited by 15
The safety of pharmacologic options for the treatment of persons with hemophilia
Franchini, M., & Mannucci, P. M. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1208747 · Cited by 15
Lock, J., Raat, H., Peters, M., Scholten, M., Beijlevelt, M., Oostenbrink, R., Leebeek, F. W. G., Moll, H. A., & Cnossen, M. H. (2016) · Haemophilia · doi:10.1111/hae.13043 · Cited by 17
Pharmacokinetic Studies of Factor VIII in Chinese Boys with Severe Hemophilia A
Chen, Z., Li, P., Li, G., Tang, L. F. P., Zhen, Y., Wu, X., Cheng, X., Luke, K. H., Blanchette, V. S., Poon, M., et al. (2018) · Chinese Medical Journal · doi:10.4103/0366-6999.233604 · Cited by 15
“Chinese Medical Journal ¦ August 5, 2018 ¦ Volume 131 ¦ Issue 15 1781 in life before the onset of joint damage.[2,3] The classic prophylaxis protocol (the Malmo protocol) involves the infusion of 20–40 FVIII IU/kg (average 30 FVIII IU/kg) on alternate days, minimum three times per week.”
BackgroundPrevention and Management of Bleeding Episodes in Children with Hemophilia
Ljung, R. C. R. (2018) · Pediatric Drugs · doi:10.1007/s40272-018-0307-z · Cited by 17
Hughes, T. S., Brok-Kristensen, M., Gargeya, Y., Lottrup, A. M. W., Larsen, A. B., Torres‐Ortuño, A., Mackett, N., & Stevens, J. (2020) · The Journal of Haemophilia Practice · doi:10.17225/jhp00151 · Cited by 15
“Despite these encouraging developments in treatment in recent generations ([6-9]), people with haemophilia (PwH) still face many challenges related to their condition in their everyday lives.”
BackgroundCuesta‐Barriuso, R., Gómez‐Conesa, A., & Pina, J. A. L. (2020) · Haemophilia · doi:10.1111/hae.14181 · Cited by 15
Abdi, A., Eckhardt, C. L., van Velzen, A. S., Vuong, C., Coppens, M., Castaman, G., Hart, D., Hermans, C. R. J. R., Gorkom, B. A. P. L., Leebeek, F. W. G., et al. (2021) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15419 · Cited by 18
“Family history inhibitors (%) 7 (11) 3 (2) 1 (4) 1 (1)”
Arteriovenous fistula as stable venous access in children with severe haemophilia
Mancuso, M. E., & Berardinelli, L. (2010) · Haemophilia · doi:10.1111/j.1365-2516.2009.02158.x · Cited by 15
Khanum, F., Bowen, D. J., Kerr, B. C., & Collins, P. W. (2013) · Haemophilia · doi:10.1111/hae.12326 · Cited by 15
Meeting unmet needs in inhibitor patients
Blanchette, V. S., & Manco‐Johnson, M. J. (2010) · Haemophilia · doi:10.1111/j.1365-2516.2010.02260.x · Cited by 15
Self-citationHemophilias and Other Disorders of Hemostasis
Shavit, J. A., & Ginsburg, D. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-383834-6.00077-x · Cited by 18
Lasting power of new clotting proteins
Powell, J. S. (2014) · Hematology · doi:10.1182/asheducation-2014.1.355 · Cited by 15
Rodriguez-Merchan, E. C., la Corte‐Rodríguez, H. D., Román, M. T. Á., Gómez-Cardero, P., & Jiménez‐Yuste, V. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11247475 · Cited by 14
The hidden joint in children with haemophilia on prophylaxis
Daffunchio, C., Galatro, G. A., Faurlin, V., Neme, D., & Caviglia, H. A. (2023) · Thrombosis Research · doi:10.1016/j.thromres.2023.04.012 · Cited by 14
Efanesoctocog alfa for the prevention and treatment of bleeding in patients with hemophilia A
Konkle, B. A. (2023) · Expert Review of Hematology · doi:10.1080/17474086.2023.2223925 · Cited by 16
Primary total knee arthroplasty in hemophilic arthropathy
Beckers, G., Massé, V., Vendittoli, P., & Morcos, M. W. (2023) · EFORT Open Reviews · doi:10.1530/eor-23-0101 · Cited by 21
Gualtierotti, R., Giachi, A., Truma, A., Arcudi, S., Ciavarella, A., Bucciarelli, P., Consonni, D., Boccalandro, E. A., Begnozzi, V., Solimeno, L. P., et al. (2024) · Haemophilia · doi:10.1111/hae.15030 · Cited by 14
Gene therapy in hemophilia: the dawn of a new era
Gualtierotti, R., Giachi, A., Bitto, N., Mura, V. L., & Peyvandi, F. (2024) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2024.102640 · Cited by 17
“While a minimum trough plasma factor level of 1% was recommended some years ago, Manco-Johnson et al. [4] demonstrated that patients treated with prophylaxis with a FVIII trough level > 1% may still develop subclinical joint damage.”
Prophylaxis in patients with von Willebrand disease: who, when, how?
Federici, A. B. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13036 · Cited by 14
Prevalence of clinical hip abnormalities in haemophilia A and B: an analysis of the UDC database
Kelly, D., Zhang, Q. C., Soucie, J. M., Manco‐Johnson, M. J., & DiMichele, D. (2012) · Haemophilia · doi:10.1111/hae.12073 · Cited by 16
“Prophylactic factor administration has been shown to prevent joint destruction and to decrease the frequency of all joint haemorrhage [5–8].”
Self-citationRanta, S., Viljakainen, H. T., Mäkipernaa, A., & Mäkitie, O. (2012) · Haemophilia · doi:10.1111/j.1365-2516.2012.02880.x · Cited by 14
Wu, R., Wu, X., Zhang, N., Zhao, L., Zhang, J., Luke, K. H., Poon, M., Peng, Y., & Doria, A. S. (2014) · Haemophilia · doi:10.1111/hae.12394 · Cited by 14
Villarrubia, R., Oyagüez, I., Álvarez‐Román, M. T., Mingot‐Castellano, M. E., Parra, R., & Casado, M. Á. (2015) · Haemophilia · doi:10.1111/hae.12681 · Cited by 14
Sabet, A., Strauss, A. C., Schmolders, J., Bornemann, R., Sabet, A., Oldenburg, J., Pennekamp, P. H., Biersack, H. J., & Ezziddin, S. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3549-4 · Cited by 14
Berntorp, E. E. (2017) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13682 · Cited by 14
Coppola, A., Franchini, M., Castaman, G., Santagostino, E., Santoro, C., Santoro, R., Morfini, M., Minno, G. D., Rocino, A., & on behalf of the AICE ad hoc Working Group (2018) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0038-1648230 · Cited by 17
Wu, R., Li, X., Yao, W., Zhang, Q., Zhou, M., Zhang, N., Yang, S., Chen, Z., Wang, Y., Kuang, Y., et al. (2021) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12552 · Cited by 14
Self-citationDelgado‐Flores, C. J., García‐Gomero, D., Salvador-Salvador, S., Montes-Alvis, J., Herrera-Cunti, C., & Taype-Rondán, Á. (2022) · PLoS ONE · doi:10.1371/journal.pone.0262273 · Cited by 15
“Two papers reported results from the Joint Outcome Study: Hacker 2007 [17] and Manco-Johnson 2007 [18]; and other two papers reported results from SPINART study: Manco-Johnson 2013 [19] and Manco-Johnson 2017 [20].”
Health technology assessment for gene therapies in haemophilia
O’Hara, J., & Neumann, P. J. (2022) · Haemophilia · doi:10.1111/hae.14413 · Cited by 15
Gene therapy – are we ready now?
Kaczmarek, R. (2022) · Haemophilia · doi:10.1111/hae.14530 · Cited by 15
The potential role of protease systems in hemophilic arthropathy
Hauw, W. W. S., Chia, J. S., Nandurkar, H. H., & Sashindranath, M. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007028 · Cited by 14
“Although access to prophylaxis has decreased the frequency of HA because reduced joint bleeding preserves joint health,(6) joint damage can still result from only a small number of hemarthroses.(7) Therefore, it remains prominent in Europe and the United States, where fair access to replacement therapy is routinely pr…”
BackgroundGene therapy for hemophilia: looking beyond factor expression
Yamaguti-Hayakawa, G. G., & Ozelo, M. C. (2022) · Experimental Biology and Medicine · doi:10.1177/15353702221147565 · Cited by 16
Gene therapy for hemophilia, a clinical viewpoint
Chou, S., Hsu, Y., & Lin, S. (2023) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2023.05.008 · Cited by 16
Unmeasured costs of haemophilia: the economic burden on families with children with haemophilia
Price, V. E., Hawes, S. A., Bouchard, A., Vaughan, A., Jarock, C., & Kuhle, S. (2015) · Haemophilia · doi:10.1111/hae.12715 · Cited by 14
Carcao, M. D., Chambost, H., & Ljung, R. C. R. (2010) · Haemophilia · doi:10.1111/j.1365-2516.2009.02196.x · Cited by 14
Beyond patient benefit: clinical development in hemophilia
Auerswald, G., Šalek, S. Z., Benson, G. M., Elezović, I. V., Lambert, T., Morfini, M., Pasi, J., Remor, E., Santagostino, E., Salaj, P., et al. (2012) · Hematology · doi:10.1179/102453312x13221316477372 · Cited by 14
Powell, J. S., & Miguelino, M. G. (2014) · Patient Preference and Adherence · doi:10.2147/ppa.s54951 · Cited by 15
“Previous studies have reported clear medical benefits with early individualized prophylactic therapy in hemophilia.(5,32) Not all individuals with severe hemophilia B can adhere to the strict requirements of frequent infusions with previous short-acting therapies.”
Stephensen, D., Drechsler, W. I., & Scott, O. M. (2013) · Haemophilia · doi:10.1111/hae.12317 · Cited by 14
Inhibitors and prophylaxis in paediatric haemophilia patients: Focus on the German experience
Kurnik, K., Auerswald, G., & Kreuz, W. (2013) · Thrombosis Research · doi:10.1016/j.thromres.2013.10.017 · Cited by 15
A Public Health Approach to the Prevention of Inhibitors in Hemophilia
Soucie, J. M., Miller, C. H., Kelly, F. M., Oakley, M. A., Brown, D., & Kucab, P. (2014) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2014.07.007 · Cited by 14
Self-citationBrown, S. A., Barnes, C., Curtin, J. A., Dunkley, S. M., Ockelford, P., Phillips, J. K., Rowell, J., Smith, M. P., & Tran, H. A. (2012) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2012.02942.x · Cited by 14
Climbing therapy under PK-tailored prophylaxis
Schmit, E., Czepa, D., Kurnik, K., Spannagl, M., & Stemberger, M. (2014) · Hämostaseologie · doi:10.5482/hamo-14-01-0003 · Cited by 14
Low‐dose prophylaxis for severe haemophilia: a little goes a long way
Fischer, K. (2015) · Haemophilia · doi:10.1111/hae.12853 · Cited by 14
Tobase, P., Lane, H. D., Siddiqi, A., Ingram‐Rich, R., & Ward, R. S. (2016) · Haemophilia · doi:10.1111/hae.12932 · Cited by 14
Sporting Activities and Quality of Life in Children With Hemophilia: An Observational Study
Cuesta‐Barriuso, R., Torres‐Ortuño, A., Pérez‐Alenda, S., Carrasco, J. J., Querol, F., & Nieto‐Munuera, J. (2016) · Pediatric Physical Therapy · doi:10.1097/pep.0000000000000296 · Cited by 14
Hong, W., Raunig, D. L., & Lundin, B. (2016) · Haemophilia · doi:10.1111/hae.13022 · Cited by 14
Balance evaluation in haemophilic preadolescent patients using Nintendo Wii Balance Board®
Pérez‐Alenda, S., Carrasco, J. J., Aguilar‐Rodríguez, M., Martínez‐Gómez, L., Querol-Giner, M., Cuesta‐Barriuso, R., Torres‐Ortuño, A., & Querol, F. (2016) · Haemophilia · doi:10.1111/hae.13128 · Cited by 14
Khair, K., Ranta, S., Thomas, A., Lindvall, K., & PedNet study group (2017) · Haemophilia · doi:10.1111/hae.13241 · Cited by 14
Ferreira, A., Leite, I. C. G., & Duncan, N. (2017) · Hematology Transfusion and Cell Therapy · doi:10.1016/j.bjhh.2017.09.002 · Cited by 14
Doshi, B. S., Raffini, L. J., & George, L. A. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14740 · Cited by 14
Rossbach, C. (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s5217 · Cited by 14
“Results of the Joint Outcome Study (JOS) conducted in the United States were published in 2007.(65) This trial enrolled 65 boys from 1996 to 2000.”
Men, Masculinities, and Hemophilia
Kalmar, L., Oliffe, J. L., Currie, L. M., Jackson, S. C., & Gue, D. (2015) · American Journal of Men s Health · doi:10.1177/1557988315596362 · Cited by 14
Jaramillo, H. E. C., Viscaya, M. M., & Mejia, A. E. (2016) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462316000544 · Cited by 16
Unmet needs in hemophilic arthropathy
Dargaud, Y. G., Lobet, S., Roussel, N. A., & Valentino, L. A. (2025) · Blood Reviews · doi:10.1016/j.blre.2025.101304 · Cited by 13
Self-citationYoneyama, K., Schmitt, C., Chang, T. Y., Dhalluin, C., Nagami, S., Petry, C., & Levy, G. G. (2021) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1968 · Cited by 14
Long-term prophylaxis: what are our options and how to define success?
Manco‐Johnson, M. J., & Warren, B. B. (2022) · Hematology · doi:10.1182/hematology.2022000397 · Cited by 14
Self-citationCarulli, C., Innocenti, M., Tambasco, R., Perrone, A., & Civinini, R. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12134356 · Cited by 13
Karpf, D. M., Kjalke, M., Thim, L., Agersø, H., Merricks, E. P., DeFriess, N., Nichols, T. C., & Ezban, M. (2011) · Haemophilia · doi:10.1111/j.1365-2516.2011.02580.x · Cited by 13
“In young boys, prophylaxis with recombinant FVIII (rFVIII) concentrate decreases the frequency of haemorrhages and prevents joint damage compared with episodic treatment at the time of haemarthrosis [4].”
BackgroundSafety of fascial therapy in adult patients with hemophilic arthropathy of ankle. A cohort study
Donoso‐Úbeda, E., Meroño‐Gallut, J., Pina, J. A. L., & Cuesta‐Barriuso, R. (2018) · Musculoskeletal Science and Practice · doi:10.1016/j.msksp.2018.03.003 · Cited by 13
Manual therapy in the treatment of patients with hemophilia B and inhibitor
Cuesta‐Barriuso, R., & Trelles‐Martínez, R. (2018) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-018-1934-9 · Cited by 13
“Pharmacological treatment involves the intravenous administration of concentrates of the missing clotting factor, either periodically (prophylactic treatment) or in the event of bleeding (on demand) [1].”
BackgroundTorres‐Ortuño, A., Cuesta‐Barriuso, R., Nieto‐Munuera, J., Galindo‐Piñana, P., & Pina, J. A. L. (2018) · Vox Sanguinis · doi:10.1111/vox.12669 · Cited by 13
Therapeutic Advances in Hematology
Kolibaba, K. S., Sterchele, J. A., Joshi, A. D., Forsyth, M., Alwon, E., Beygi, H., & Kennealey, G. T. (2013) · Cited by 13
Nichols, T. C., Levy, H. A., Merricks, E. P., Raymer, R. A., & Lee, M. L. (2020) · PLoS ONE · doi:10.1371/journal.pone.0240896 · Cited by 13
“Routine prophylaxis can substantially reduce bleeding episodes [11–13], prevent joint diseases [11, 14] and reduce the risk of death, but unfortunately, many patients do not receive prophylaxis and need to treat bleeding episodes on-demand [15, 16].”
BackgroundLü, M., Oladapo, A. O., Wu, Y., Farahbakhshian, S., & Ewenstein, B. M. (2020) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2020.20327 · Cited by 13
Jiménez‐Yuste, V., la Corte‐Rodríguez, H. D., Román, M. T. Á., Martín‐Salces, M., Querol, F., Bonanad, S., Mingot‐Castellano, M. E., Fernández‐Mosteirín, N., Canaro, M., Santamaría, A., et al. (2021) · Haemophilia · doi:10.1111/hae.14280 · Cited by 13
Efficacy and safety of subcutaneous prophylaxis with dalcinonacog alfa in adults with haemophilia B
Mahlangu, J. N., Levy, H. A., Lee, M., & Greco, F. D. (2021) · Haemophilia · doi:10.1111/hae.14315 · Cited by 13
Nonfactor Therapies: New Approaches to Prophylactic Treatment of Haemophilia
Chowdary, P. (2021) · Hämostaseologie · doi:10.1055/a-1424-7900 · Cited by 14
Pasi, J., Hermans, C. R. J. R., Hakimi, Z., Nazir, J., Aballéa, S., Ezzalfani, M., & Fatoye, F. (2022) · Therapeutic Advances in Hematology · doi:10.1177/20406207221079482 · Cited by 13
Huang, K., Wang, Y., Zhen, Y., Li, G., Wu, X., Zhang, N., Chen, Z., & Wu, R. (2022) · Thrombosis Research · doi:10.1016/j.thromres.2022.03.008 · Cited by 13
Liver gene therapy with intein‐mediated F8 trans‐splicing corrects mouse haemophilia A
Esposito, F., Lyubenova, H., Tornabene, P., Auricchio, S., Iuliano, A., Nusco, E., Merlin, S., Olgasi, C., Manni, G., Gargaro, M., et al. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202115199 · Cited by 13
“%) can significantly reduce the risk of spontaneous bleeding events and the need for F8 replacement infusions (Manco-Johnson et al, 2007).”
BackgroundElsheikh, E., Lavin, M., Antunes, L., Larkin, N., Mullaney, B., Doherty, D., Kennedy, M., Keenan, C., Guest, T., O’Mahony, B., et al. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2023.01.013 · Cited by 16
Berntorp, E. E. (2013) · Haemophilia · doi:10.1111/hae.12100 · Cited by 13
Spira, J., Plyushch, O. P., Andreeva, T. A., Zorenko, V. Y., Zozulya, N. I., Velichkoi, I., Zalepukhina, O. E., Yatuv, R., & Baru, M. (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2012.09115.x · Cited by 13
Zhou, Z., & Hay, J. W. (2012) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.01.001 · Cited by 13
Villaça, P. R., Carneiro, J. D. A., D’Amico, É. A., Blanchette, V. S., Brandão, L. R., Cassis, F., Santos, V. N., Sandoval, E. P. N., Burke, T. A., & Young, N. L. (2013) · Haemophilia · doi:10.1111/hae.12213 · Cited by 13
Multidimensional Genome-wide Analyses Show Accurate FVIII Integration by ZFN in Primary Human Cells
Sivalingam, J., Kenanov, D., Han, H., Nirmal, A. J., Ng, W. H., Lee, S. S., Masilamani, J., Phan, T. T., Maurer‐Stroh, S., & Kon, O. L. (2015) · Molecular Therapy · doi:10.1038/mt.2015.223 · Cited by 14
Hämophiliebehandlung in Österreich
Pabinger, I., Heistinger, M., Muntean, W. E., Reitter-Pfoertner, S., Rosenlechner, S., Schindl, T., Schuster, G., Streif, W., Thom, K., & Male, C. (2015) · Wiener klinische Wochenschrift · doi:10.1007/s00508-015-0872-x · Cited by 13
Zourikian, N., Merlen, C., Bonnefoy, A., St‐Louis, J., & Rivard, G. (2016) · Haemophilia · doi:10.1111/hae.12869 · Cited by 13
Risks and patient outcomes of surgical intervention for hemophilic arthropathy
Rodriguez-Merchan, E. C. (2019) · Expert Review of Hematology · doi:10.1080/17474086.2019.1602035 · Cited by 13
Nagao, A., Suzuki, N., Takedani, H., Yamasaki, N., Chikasawa, Y., Sawada, A., Kanematsu, T., Nojima, M., Higasa, S., Amano, K., et al. (2019) · Haemophilia · doi:10.1111/hae.13749 · Cited by 13
Is Low Dose a New Dose to Initiate Hemophilia A Prophylaxis? – A Systematic Study in Eastern India
Gulshan, S., Mandal, P. K., Phukan, A., Baul, S. N., De, R., Dolai, T. K., & Chakrabarti, P. (2020) · The Indian Journal of Pediatrics · doi:10.1007/s12098-019-03179-w · Cited by 13
“Once joint damage has occurred, it progresses over the patient’s lifetime even if no further bleeds occur in the affected joints [7].”
BackgroundForsyth, A. L., Blamey, G., Lobet, S., & McLaughlin, P. (2020) · Health · doi:10.4236/health.2020.122014 · Cited by 15
Metadata
- Authors
- Manco-Johnson, M. J., Abshire, T. C., Shapiro, A. D., Riske, B., Hacker, M. R., Kilcoyne, R., Ingram, J. D., Manco-Johnson, M. L., Funk, S., Jacobson, L., Valentino, L. A., Hoots, W. K., Buchanan, G. R., DiMichele, D., Recht, M., Brown, D., Leissinger, C., Bleak, S., Cohen, A., Mathew, P., Matsunaga, A., Medeiros, D., Nugent, D., Thomas, G. A., Thompson, A. A., McRedmond, K., Soucie, J. M., Austin, H., & Evatt, B. L.
- Affiliations
- University of Colorado Denver (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-08-09
- Volume
- 357
- Issue
- 6
- Pages
- 535-544
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2167801052
- Cited by
- 1,950
- References
- 27
- Citations by year
- 2026: 57 · 2025: 70 · 2024: 98 · 2023: 115 · 2022: 106 · 2021: 123 · 2020: 127 · 2019: 110 · 2018: 114 · 2017: 107 · 2016: 123 · 2015: 116 · 2014: 131 · 2013: 116 · 2012: 112
- FWCI
- 45.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Public Health Service (U27/CCU812106, R00069)
- Topics
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Health Sciences › Medicine › Hematology › Blood transfusion and management
- Keywords
- hemophilia A, severe hemophilia, prophylaxis, episodic treatment, recombinant factor VIII, joint destruction, factor VIII inhibitors, joint hemorrhage, children, central venous catheter complications
- MeSH terms
- Child, Child, Preschool, Drug Administration Schedule, Factor VIII, Follow-Up Studies, Hemarthrosis, Hemophilia A, Hemorrhage, Humans, Infant, Infusions, Intravenous, Joint Diseases, Male, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.